• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - Product Image

Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  • ID: 1936740
  • October 2011
  • 90 pages
  • GlobalData

FEATURED COMPANIES

  • AstraZeneca PLC
  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • MORE

Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global influenza vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global influenza vaccines vaccines market was valued at $3,525.1m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.8% over the next seven years, to reach $5,242.9m READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca PLC
  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Influenza Vaccines - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Types of Influenza Virus
2.3.2 Source of Influenza Virus
2.3.3 Drifting and Shifting of Influenza Virus
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Options
2.7 GlobalData Pipeline Report Guidance
3 Influenza Vaccines: Market Characterization
3.1 Influenza Vaccines Market Size (2005-2010) – Global
3.2 Influenza Vaccines Market Forecast (2011-2018) – Global
3.3 Influenza Vaccines Market Size (2005-2010) – The US
3.4 Influenza Vaccines Market Forecast (2011-2018) – The US
3.5 Influenza Vaccines Market Size (2005-2010) – France
3.6 Influenza Vaccines Market Forecast (2011-2018) – France
3.7 Influenza Vaccines Market Size (2005-2010) – Germany
3.8 Influenza Vaccines Market Forecast (2011-2018) – Germany
3.9 Influenza Vaccines Market Size (2005-2010) – Italy
3.10 Influenza Vaccines Market Forecast (2011-2018) – Italy
3.11 Influenza Vaccines Market Size (2005-2010) – Spain
3.12 Influenza Vaccines Market Forecast (2011-2018) – Spain
3.13 Influenza Vaccines Market Size (2005-2010) – The UK
3.14 Influenza Vaccines Market Forecast (2011-2018) – The UK
3.15 Influenza Vaccines Market Size (2005-2010) – Japan
3.16 Influenza Vaccines Market Forecast (2011-2018) – Japan
3.17 Drivers and Barriers for the Influenza Vaccines Market
3.17.1 Drivers for the Influenza Vaccines Market
3.17.2 Barriers for the Influenza Vaccines Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Influenza Vaccines: Competitive Assessment
4.1 Overview
4.2 5.1.1 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Influenza Vaccines Market
4.3.1 Fluarix
4.3.2 FluLaval
4.3.3 Flumist
4.3.4 Fluvirin
4.3.5 Fluzone
4.4 Key Takeaway
5 Influenza Vaccines - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Influenza Vaccines Pipeline – Pipeline by Phases of Development
5.2.2 Influenza Vaccines – Regulatory Filed Products
5.2.3 Influenza Vaccines – Phase III Pipeline
5.2.4 Influenza Vaccines – Phase II Pipeline
5.2.5 Influenza Vaccines – Phase I Pipeline
5.2.6 Influenza Vaccines – Pre-Clinical Pipeline
5.2.7 Influenza Vaccines – Discovery Pipeline
5.2.8 Technology Trends Analytical Framework
5.3 Influenza Vaccines – Clinical Pipeline by Types of Vaccine
5.4 Influenza Vaccines – Promising Drugs Under Clinical Development
5.5 Molecule Profile for Promising Drugs Under Clinical Development
5.5.1 FluBlok
5.5.2 Flu Vaccine
5.5.3 MEDI 3250
5.5.4 A-04-01D Vaccine
5.5.5 H5N1 Pandemic Influenza Vaccine
5.5.6 Vepacel
5.6 Key Takeaway
6 Influenza Vaccines: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Influenza Vaccines Clinical Trials
7 Influenza Vaccines: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Influenza Vaccines: Implications for Future Market Competition
8 Influenza Vaccines: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 AstraZeneca PLC
8.2.2 GlaxoSmithKline plc
8.2.3 Novartis AG
8.2.4 Baxter International Inc.
9 Influenza Vaccines: Licensing and Partnership Deals
10 Influenza Vaccines: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Influenza Vaccines Market, Global, Revenue ($m), 2005–2010
Table 2: Influenza Vaccines Market, Global, Forecast ($m), 2011–2018
Table 3: Influenza Vaccines Market, The US, Revenue ($m), 2005–2010
Table 4: Influenza Vaccines Market, The US, Forecasts ($m), 2011–2018
Table 5: Influenza Vaccines Market, France, Revenue ($m), 2005–2010
Table 6: Influenza Vaccines Market, France, Forecasts ($m), 2011–2018
Table 7: Influenza Vaccines Market, Germany, Revenue ($m), 2005–2010
Table 8: Influenza Vaccines Market, Germany, Forecasts ($m), 2011–2018
Table 9: Influenza Vaccines Market, Italy, Revenue ($m), 2005–2010
Table 10: Influenza Vaccines Market, Italy, Forecasts ($m), 2011–2018
Table 11: Influenza Vaccines Market, Spain, Revenue ($m), 2005–2010
Table 12: Influenza Vaccines Market, Spain, Forecasts ($m), 2011–2018
Table 13: Influenza Vaccines Market, The UK, Revenue ($m), 2005–2010
Table 14: Influenza Vaccines Market, The UK, Forecasts ($m), 2011–2018
Table 15: Influenza Vaccines Market, Japan, Revenue ($m), 2005–2010
Table 16: Influenza Vaccines Market, Japan, Forecasts ($m), 2011–2018
Table 17: Influenza Vaccines – Regulatory Filed Products, 2011
Table 18: Influenza Vaccines – Phase III Pipeline, 2011
Table 19: Influenza Vaccines – Phase II Pipeline, 2011
Table 20: Influenza Vaccines – Phase I Pipeline, 2011
Table 21: Influenza Vaccines – Pre-Clinical Pipeline, 2011
Table 22: Influenza Vaccines – Discovery Pipeline, 2011
Table 23: Influenza Vaccines – Most Promising Drugs Under Clinical Development, 2011
Table 24: Influenza Vaccines – Clinical Trials by Country, 2011
Table 25: Influenza Vaccines – Clinical Trials by Phase, 2011
Table 26: Influenza Vaccines – Clinical Trials by Status, 2011
Table 27: Influenza Vaccines – Overall Sponsors, 2011
Table 28: Influenza Vaccines – Prominent Sponsors, 2011
Table 29: Influenza Vaccines – Top Companies Participating in Clinical Trials, 2011
Table 30: Astrazeneca - Influenza Pipeline Products, 2011
Table 31: GlaxoSmithKline - Influenza Pipeline Products, 2011
Table 32: Novartis AG - Influenza Pipeline Products, 2011
Table 33: Baxter International - Influenza Pipeline Products, 2011
Table 34: Influenza Vaccines: Licensing and Partnership Deals, 2011

1.2 List of Figures
Figure 1: Comparison of Seasonal and Pandemic Influenza
Figure 2: Comparison of Influenza A, B and C
Figure 3: Comparison of Influenza and the Common Cold
Figure 4: Influenza Virus Testing Methods
Figure 5: Clinical Algorithm for Consideration in the Assessment of Persons with Mild or Uncomplicated Influenza Illness
Figure 6: Influenza Vaccines Market, Global, Revenue ($m), 2005–2010
Figure 7: Influenza Vaccines Market, Global, Forecast ($m), 2011–2018
Figure 8: Influenza Vaccines Market, The US, Revenue ($m), 2005–2010
Figure 9: Influenza Vaccines Market, The US, Forecast ($m), 2011–2018
Figure 10: Influenza Vaccines Market, France, Revenue ($m), 2005–2010
Figure 11: Influenza Vaccines Market, France, Forecast ($m), 2011–2018
Figure 12: Influenza Vaccines Market, Germany, Revenue ($m), 2005–2010
Figure 13: Influenza Vaccines Market, Germany, Forecast ($m), 2011–2018
Figure 14: Influenza Vaccines Market, Italy, Revenue ($m), 2005–2010
Figure 15: Influenza Vaccines Market, Italy, Forecast ($m), 2011–2018
Figure 16: Influenza Vaccines Market, Spain, Revenue ($m), 2005–2010
Figure 17: Influenza Vaccines Market, Spain, Forecast ($m), 2011–2018
Figure 18: Influenza Vaccines Market, The UK, Revenue ($m), 2005–2010
Figure 19: Influenza Vaccines Market, The UK, Forecast ($m), 2011–2018
Figure 20: Influenza Vaccines Market, Japan, Revenue ($m), 2005–2010
Figure 21: Influenza Vaccines Market, Japan, Forecast ($m), 2011–2018
Figure 22: Opportunity and Unmet Need in the Influenza Vaccines Market
Figure 23: Influenza Vaccines – Strategic Competitor Assessment, 2010
Figure 24: Influenza Vaccines – Pipeline by Phase of Development, 2011
Figure 25: Influenza Vaccines – Technology Trends Analytics Framework, 2011
Figure 26: Influenza Vaccines – Technology Trends Analytics Framework – Description, 2011
Figure 27: Influenza Vaccines – Pipeline by Types of Vaccines, 2011
Figure 28: Influenza Vaccines – Clinical Trials by Country, 2011
Figure 29: Influenza Vaccines – Clinical Trials by Phase, 2011
Figure 30: Influenza Vaccines – Clinical Trials by Status, 2011
Figure 31: Influenza Vaccines – Overall Sponsors, 2011
Figure 32: Influenza Vaccines – Prominent Sponsors, 2011
Figure 33: Influenza Vaccines – Top Companies Participating in Clinical Trials, 2011
Figure 34: Influenza Vaccines Market, Drivers and Barriers, 2011
Figure 35: Implications for Future Market Competition in the Influenza Vaccines Market, 2011
Figure 36: Influenza Vaccines Market – Pipeline by Company, 2011
Figure 37: GlobalData Market Forecasting Model

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca PLC
  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • MORE

GlobalData, the industry analysis specialist, has released its new report, “Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global influenza vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Influenza Vaccines Market is Forecast to Show Moderate Growth Until 2018

GlobalData estimates that the global influenza vaccines market was valued at $3,525.1m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.8% over the next seven years, to reach $5,242.9m in 2018. The moderate growth of the market is due to the increasing awareness among people about the importance of vaccination against influenza, and the approval of new influenza vaccines. The universal immunization recommendation by the Advisory Committee on Immunization Practices (ACIP) and several government awareness vaccination programs would help to increase the vaccination coverage for influenza. The upcoming influenza vaccines include seasonal vaccines such as FluBlok and MEDI-3250, pandemic and pre-pandemic (mainly H5N1) vaccines such as Flu (Pre) Pandemic Vaccine, H5N1 pandemic influenza vaccine and Vepacel, and universal influenza vaccines such as BVX-M001, MVA-NP+M1, Flu-v and others. The influenza vaccines market is also set to witness the launch of quadrivalent vaccines such as Fluzone QIV, and adjuvant vaccines such as JVRS-100 with Fluzone and IC31 Seasonal Influenza Vaccine. The pipeline also includes vaccines with different routes of administration, such as oral vaccine (Avian Influenza (H5N1) Oral Vaccine), nasal vaccine (Influenza Intranasal Vaccine), vaccine in the form of nasal dry powder (GelVac), and vaccine patch (Pandemic Influenza Vaccine Patch).

Influenza Vaccines Market, Global, Revenue and Forecasts ($m), 2005–2018

Source: GlobalData, Centre for Disease Control and Prevention (CDC), Rodríguez de Azero M, the European Vaccine Manufacturers Influenza Working Group, “Trends in seasonal influenza vaccine distribution in the European Union: 2003-4 to 2007-8”, Eurosurveillance, Volume 13, Issue 43, 23 October 2008; Patricia R Blank and Thomas D Szucs “Increasing influenza vaccination coverage in recommended population groups in Europe”, 2009; “Pandemic influenza A (H1N1) vaccine policy in Japan” , Health Policy Monitor; Ministry of Health, Labour and Welfare, Japan; GlobalData Epidemiology-based Market Forecasting Model

Note: Product cover images may vary from those shown

AstraZeneca PLC
GlaxoSmithKline plc
Novartis AG
Baxter International Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos